Search

Your search keyword '"Yip, Sze-Fai"' showing total 231 results
Start Over Author "Yip, Sze-Fai"
231 results on '"Yip, Sze-Fai"'

4. Association between cognitive impairment and functional limitations in everyday life in patients with haemophilia in Hong Kong

Author

Cheung, Yin Ting, primary, Ma, Chung Tin, additional, Weishang, Deng, additional, Lam, Henry Hon Wai, additional, Ling, Siu Cheung, additional, Kwok, Kevin, additional, Li, Chak Ho, additional, Ha, Chung Yin, additional, Yip, Sze Fai, additional, Siu Ming Wong, Raymond, additional, Chu, Winnie Chiu Wing, additional, and Li, Chi Kong, additional

Published
2024
Full Text
View/download PDF

6. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Au, Wing-Yan, Chiu, Brian, Fan, Lei, Li, Zheng, LAM, Tai Hing, Liang, Raymond, Yeh, Su-Peng, Xu, Jun, Ip, Dennis Kai Ming, Li, Gandi, Xu, Gang, Wang, Xiaodong, Bai, Ou, Cai, Qing-Qing, Xia, Yi, Chen, Jie-Rong, Luo, Chun-Ling, Xiong, Xiang-Yu, Zeng, Yanni, Wei, Pan-Pan, Liu, Chu-Jun, Liu, Yu-Xiang, Cao, Yu-Lu, He, Shuai, Liu, Yang, Ha, Jeslin Chian Hung, Khoo, Lay Poh, Kee, Rebecca Xiangpin, Tan, Jing, Liu, Yanhui, Zhang, Fen, Feng, Yanfen, Rao, Huilan, Chng, Wee Joo, Chan, Jason Yong Sheng, Somasundaram, Nagavalli D/O, Tao, Miriam, Ras, Mohamad Farid Bin Harunal, Yeoh, Kheng-Wei, Goh, Yeow Tee, Ong, Shin Yeu, Grigoropoulos, Nicholas Francis, Wong, Esther Kam Yin, Pang, Jane Wan Lu, Lim, Jing Quan, Chia, Burton Kuan Hui, Kim, Seok Jin, Yoon, Sang Eun, Choi, Seungkyu, Kuo, Ching-Yuan, Chen, Tsai-Yun, Su, Yu-Chieh, Huang, Wen-Tsung, Lee, Ming-Yang, Yao, Wenxiu, Ngan, Kai-Cheong, Liu, Herman, Lee, Harold, Yip, Sze-Fai, Liu, Jie, Li, Jianyong, Rabkin, Charles S., Berndt, Sonja, Bassig, Bryan, Hu, Wei, Zhao, Mingfeng, Li, Yuming, Zhai, Qiongli, Shao, Zonghong, Qiu, Lugui, Wang, Jianxiang, Xu, Fu-Ping, Chen, Ling, Hou, Yu, Xu, Shuangnian, Huang, Zhen, Xie, Mingling, Li, Ming, Zhong, Shilong, Zhang, Yan, Gu, Dongqing, Wang, Xin, Foo, Jia Nee, Li, Zhiqiang, Dai, Juncheng, Sun, Liangdan, Wang, Zhenzhen, Liu, Hong, Zhou, Hui, Sun, Yonghu, Koh, Woon-Puay, Heng, Chew-Kiat, Hong, Chew Soo, Ahn, Jeeyun, Park, Kyu Hyung, Tin, Aung, Gu, Jieruo, Xia, Xiaojun, Li, Bo, Yu, Xueqing, Lin, Guo-Wang, Xu, Caigang, Chen, Kexin, Huang, Hui-Qiang, Chen, Jieping, Song, Bao, Chan, John K C, Li, Wenyu, Liu, Weiping, Shih, Lee-Yung, Chuang, Wen-Yu, Kim, Won Seog, Tan, Wen, Peng, Rou-Jun, Laurensia, Yurike, Cheah, Daryl Ming Zhe, Huang, DaChuan, Cheng, Chee Leong, Su, Yi-Jiun, Tan, Soo-Yong, Ng, Siok-Bian, Tang, Tiffany Pooi Ling, Han, Kyudong, Wang, Vivien Ya-Fan, Jia, Wei-Hua, Pei, Zhong, Li, Ya-Jun, Gao, Song, Shi, Yongyong, Hu, Zhibin, Zhang, Furen, Zhang, Ben, Zeng, Yi-Xin, Shen, Hongbing, He, Lin, Ong, Choon Kiat, Lim, Soon Thye, Chanock, Stephen, Kwong, Yok-Lam, Lin, Dongxin, Rothman, Nathaniel, Khor, Chiea Chuen, Lan, Qing, and Bei, Jin-Xin

Published
2020
Full Text
View/download PDF

7. PB2674: CLINICAL, NEUROIMAGING, AND BEHAVIORAL RISK FACTORS FOR NEUROCOGNITIVE IMPAIRMENT IN CHINESE PATIENTS WITH HEMOPHILIA: A MULTICENTER STUDY

Author

Cheung, Yin Ting, primary, MA, Chung Tin Justin, additional, Lam, Henry Hon Wai, additional, Ling, Siu Cheung, additional, Kwok, Kevin, additional, LI, Chak Ho, additional, Ha, Chung Yin, additional, Yip, Sze Fai, additional, Wong, Raymond, additional, Chu, Winnie Chiu Wing, additional, and LI, Chi Kong, additional

Published
2023
Full Text
View/download PDF

11. Clinical, neuroimaging, and behavioural risk factors for neurocognitive impairment in Chinese patients with haemophilia: A multicentre study.

Author

Cheung, Yin Ting, Ma, Chung Tin, Lam, Henry Hon Wai, Ling, Siu Cheung, Kwok, Kevin, Li, Chak Ho, Ha, Chung Yin, Yip, Sze Fai, Wong, Raymond Siu Ming, Chu, Winnie Chiu Wing, and Li, Chi Kong

Subjects
HEMOPHILIACS, COGNITIVE processing speed, CHINESE people, CRITICAL thinking, COGNITIVE flexibility
Abstract

Background: Few studies have evaluated the impact of subclinical microstructural changes and psychosocial factors on cognitive function in patients with haemophilia. Objectives: To determine the prevalence and characteristics of cognitive impairment in patients with haemophilia, and identify associated risk factors. Methods: We recruited haemophilia A or B patients who were aged ≥10 years old from three public hospitals in Hong Kong. A neurocognitive battery was administered to evaluate their attention, memory, processing speed and cognitive flexibility performances. They also underwent magnetic resonance imaging to identify cerebral microbleeds. Validated self‐reported questionnaires were administered to assess their mental health status and adherence to prophylactic treatment. General linear modelling was used to investigate the association of neurocognitive outcomes with risks factors, adjusting for age and education attainment. Results: Forty‐two patients were recruited (median age 32.0 years; 78.6% haemophilia A; 80.9% moderate‐to‐severe disease). Six patients (14.3%) had developed cerebral microbleeds. A subgroup of patients demonstrated impairments in cognitive flexibility (30.9%) and motor processing speed (26.2%). Hemarthrosis in the previous year was associated with worse attention (Estimate = 7.62, 95% CI: 1.92–15.33; p =.049) and cognitive flexibility (Estimate = 8.64, 95% CI: 2.52–13.29; p =.043). Depressive (Estimate = 0.22, 95% CI: 0.10–0.55; p =.023) and anxiety (Estimate = 0.26, 95% CI: 0.19–0.41; p =.0069) symptoms were associated with inattentiveness. Among patients receiving prophylactic treatment (71.4%), medication adherence was positively correlated with cognitive flexibility (p =.037). Conclusion: A substantial proportion of patients with haemophilia demonstrated cognitive impairment, particularly higher‐order thinking skills. Screening for cognitive deficits should be incorporated into routine care. Future studies should evaluate the association of neurocognitive outcomes with occupational/vocational outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. sj-docx-1-tah-10.1177_20406207221082043 – Supplemental material for The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain

Author

Tang, Hoi Ki Karen, Fung, Chi Yeung, Morgan, Gareth J., Kumar, Shaji, Siu, Lisa, Ip, Ho Wan Alvin, Yip, Sze Fai, Lau, Ka Ngai Harry, Lau, Chi Kuen, Lee, Harold, Leung, Kwan Hung, Kho, Bonnie, Wong, Howard, Ngai, Cheong, Hwang, Yu Yan, Sim, Joycelyn, Kwong, Yok Lam, and Chim, Chor Sang

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207221082043 for The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain by Hoi Ki Karen Tang, Chi Yeung Fung, Gareth J. Morgan, Shaji Kumar, Lisa Siu, Ho Wan Alvin Ip, Sze Fai Yip, Ka Ngai Harry Lau, Chi Kuen Lau, Harold Lee, Kwan Hung Leung, Bonnie Kho, Howard Wong, Cheong Ngai, Yu Yan Hwang, Joycelyn Sim, Yok Lam Kwong and Chor Sang Chim in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

15. SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response.

Author

Pitts, Herbert Augustus, Cheng, Chi-Keung, Cheung, Joyce Sin, Sun, Murphy Ka-Hei, Yung, Yuk-Lin, Chan, Hoi-Yun, Wong, Raymond S. M., Yip, Sze-Fai, Lau, Ka-Ngai, Wong, Wai Shan, Raghupathy, Radha, Chan, Natalie P. H., and Ng, Margaret H. L.

Subjects
IMMUNOREGULATION, PROTEIN expression, PROGNOSIS, P53 antioncogene, ACUTE myeloid leukemia, CYTOGENETICS
Abstract

There is an urgent need for the identification as well as clinicopathological and functional characterization of potent prognostic biomarkers and therapeutic targets in acute myeloid leukemia (AML). Using immunohistochemistry and next-generation sequencing, we investigated the protein expression as well as clinicopathological and prognostic associations of serine protease inhibitor Kazal type 2 (SPINK2) in AML and examined its potential biological functions. High SPINK2 protein expression was an independent adverse biomarker for survival and an indicator of elevated therapy resistance and relapse risk. SPINK2 expression was associated with AML with an NPM1 mutation and an intermediate risk by cytogenetics and European LeukemiaNet (ELN) 2022 criteria. Furthermore, SPINK2 expression could refine the ELN2022prognostic stratification. Functionally, an RNA sequencing analysis uncovered a potential link of SPINK2 with ferroptosis and immune response. SPINK2 regulated the expression of certain P53 targets and ferroptosis-related genes, including SLC7A11 and STEAP3, and affected cystine uptake, intracellular iron levels and sensitivity to erastin, a specific ferroptosis inducer. Furthermore, SPINK2 inhibition consistently increased the expression of ALCAM, an immune response enhancer and promoter of T-cell activity. Additionally, we identified a potential small-molecule inhibitor of SPINK2, which requires further characterization. In summary, high SPINK2 protein expression was a potent adverse prognostic marker in AML and might represent a druggable target. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain

Author

Tang, Hoi Ki Karen, primary, Fung, Chi Yeung, additional, Morgan, Gareth J., additional, Kumar, Shaji, additional, Siu, Lisa, additional, Ip, Ho Wan Alvin, additional, Yip, Sze Fai, additional, Lau, Ka Ngai Harry, additional, Lau, Chi Kuen, additional, Lee, Harold, additional, Leung, Kwan Hung, additional, Kho, Bonnie, additional, Wong, Howard, additional, Ngai, Cheong, additional, Hwang, Yu Yan, additional, Sim, Joycelyn, additional, Kwong, Yok Lam, additional, and Chim, Chor Sang, additional

Published
2022
Full Text
View/download PDF

21. P-048: Clinical application of the weighted cytogenetic scoring system in Multiple Myeloma

Author

Hwang, Yu Yan, primary, Fung, Chi Yeung, additional, Siu, Lisa, additional, Ip, Ho Wan Alvin, additional, Yip, Sze Fai, additional, Lau, Ka Ngai Harry, additional, Lau, Chi Kuen, additional, Lee, Harold, additional, Leung, Kwan Hung, additional, Kho, Bonnie, additional, Wong, Howard, additional, Ngai, Cheong, additional, Tang, Hoi Ki Karen, additional, Sim, Joycelyn, additional, Kwong, Yok Lam, additional, and Chim, Chor Sang, additional

Published
2021
Full Text
View/download PDF

22. P-181: Treatment outcome and prognostic factors of newly diagnosed Multiple Myeloma receiving Bortezomib-based induction in Hong Kong: an analysis of 448 patients

Author

Tang, Hoi Ki Karen, primary, Fung, Chi Yeung, additional, Hwang, Yu Yan, additional, Lee, Harold, additional, Yip, Sze Fai, additional, Wong, Howard, additional, Lau, Chi Kuen, additional, Leung, Kwan Hung, additional, Au, Elaine, additional, Kho, Bonnie, additional, Tse, Eric, additional, Sim, Joycelyn, additional, Kwong, Yok Lam, additional, and Chim, Chor Sang, additional

Published
2021
Full Text
View/download PDF

23. P-062: The impact of Bortezomib-based induction on chromosome 1q21 gained newly diagnosed Multiple Myeloma of Chinese origin

Author

Tang, Hoi Ki Karen, primary, Fung, Chi Yeung, additional, Morgan, Gareth, additional, Siu, Lisa, additional, Ip, Ho Wan Alvin, additional, Yip, Sze Fai, additional, Lau, Ka Ngai Harry, additional, Wong, Howard, additional, Kho, Bonnie, additional, Lee, Harold, additional, Leung, Kwan Hung, additional, Lau, Chi Kuen, additional, Chim, Chor Sang, additional, Hwang, Yu Yan, additional, Sim, Joycelyn, additional, Ngai, Cheong, additional, and Kwong, Yok Lam, additional

Published
2021
Full Text
View/download PDF

29. Association of HLA‐B22 serotype with SARS‐CoV ‐2 susceptibility in Hong Kong Chinese patients

Author

Yung, Yuk‐Lin, primary, Cheng, Chi‐Keung, additional, Chan, Hoi‐Yun, additional, Xia, Jenny T., additional, Lau, Kin‐Mang, additional, Wong, Raymond S. M., additional, Wu, Alan K. L., additional, Chu, Raymond W., additional, Wong, Alice C. C., additional, Chow, Eudora Y. D., additional, Yip, Sze‐Fai, additional, Leung, Jennifer N. S., additional, Lee, Cheuk‐Kwong, additional, and Ng, Margaret H. L., additional

Published
2020
Full Text
View/download PDF

33. Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy.

Author

Man Fai Law, Hay Nun Chan, Shun Yin Kong, Ho Kei Lai, Chung Yin Ha, Celia Ng, Yiu Ming Yeung, Sze Fai Yip, Law, Man Fai, Chan, Hay Nun, Kong, Shun Yin, Lai, Ho Kei, Ha, Chung Yin, Ng, Celia, Yeung, Yiu Ming, and Yip, Sze Fai

Subjects
HEPATITIS B virus, DISEASE risk factors, LYMPHOBLASTIC leukemia, VIRUS reactivation, HEPATITIS B, ACUTE leukemia
Abstract

Introduction: Hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone) has become a popular regimen for adults with acute lymphoblastic leukemia (ALL). We assessed the efficacy and tolerability of hyper-CVAD in the treatment of adult ALL.Material and Methods: We retrospectively reviewed ALL patients aged 18 or above receiving the hyper-CVAD regimen. We assessed complete remission rate and overall survival, as well as hepatitis B carrier rate and hepatitis flare due to hepatitis B virus (HBV) reactivation.Results: Fifty-two patients were treated with the hyper-CVAD regimen. The median age at diagnosis was 42 years; 27% of patients were Philadelphia (Ph) chromosome positive. The complete remission (CR) rate was 90.4% after the first cycle of chemotherapy. The induction mortality rate was 1.9%. Three patients required two cycles of hyper-CVAD to achieve CR. The median overall survival was 39.6 months and the 5-year overall survival was 50%. Age over 30 years and white blood cell count of more than 30 × 109/l were found to be prognostic for poor overall survival in multivariate analysis. The hepatitis B carrier rate was 17% in our cohort, and the rate of hepatitis flare due to HBV reactivation was 11% in patients with current infection.Conclusions: Hyper-CVAD is feasible and tolerable with a good CR rate in the treatment of adult ALL patients. It is an option for the treatment of ALL. Antiviral prophylaxis should be considered in ALL patients with HBV infection to reduce the risk of HBV reactivation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Author

Bastidas, Adriana de la Serna, Javier El Idrissi, Mohamed and Oostvogels, Lidia Quittet, Philippe Lopez-Jimenez, Javier and Vural, Filiz Pohlreich, David Zuckerman, Tsila Issa, Nicolas C. Gaidano, Gianluca Lee, Je-Jung Abhyankar, Sunil and Solano, Carlos Perez de Oteyza, Jaime Satlin, Michael J. and Schwartz, Stefan Campins, Magda Rocci, Alberto Llamas, Carlos Vallejo Lee, Dong-Gun Tan, Sen Mui Johnston, Anna M. and Grigg, Andrew Boeckh, Michael J. Campora, Laura and Lopez-Fauqued, Marta Heineman, Thomas C. Stadtmauer, Edward A. and Sullivan, Keith M. Alonso Alonso, Aranzazu Anagnostopoulos, Achilles Andreadis, Charalambos (Babis) Angelopoulou, Maria and Anttila, Veli-Jukka Aoun, Mickael Barista, Ibrahim Berkahn, Leanne Bloor, Adrian J. C. Broady, Raewyn Brossart, Peter and Buadi, Francis K. Bulabois, Claude-Eric Cantin, Guy and Cellini, Claudia Chandrasekar, Pranatharthi Haran Chauncey, Thomas Cuneo, Antonio Dadwal, Sanjeet Singh Dickinson, Michael Eom, HyeonSeok Esquirol Sanfeliu, Albert Ferra Coll, Christelle Flomenberg, Phyllis R. Pilar Gonzalez-Rodriguez, Ana and Gottlieb, David J. Grisariu, Sigal Guenther, Andreas and Gutman, Jonathan Hahn, Uwe Heinz, Werner J. Heras, Inmaculada Ikeda, Takashi Jarque, Isidro Karthaus, Meinolf and Kerre, Tessa Kiani, Alexander Klein, Andreas K. Kofla, Grzegorz Kryuchkova, Irina V. Kuo, Ching-Yuan Kuruvilla, John Kuvshinov, Aleksey Kwak, Jae-Yong Lee, Jae Hoon and Lepretre, Stephane Lie, Albert Kwok-Wai Lucchesi, Alessandro and Maertens, Johan Marijt, Erik W. A. Martinez Munoz, Carmen and Michieli, Mariagrazia Milliken, Samuel T. Milpied, Noel and Monserrat Coll, Jorge Mossad, Sherif Beniameen Murphy, John and Navarro Matilla, Maria Belen Novak, Jan Olney, Harold J. Ona Navarrete, Raquel Pascual Cascon, Maria Jesus Peniket, Andy and Penka, Ganeva Piatkowska-Jakubas, Beata Polo Zarzuela, Marta and Quiel, Dimas Rowley, Scott D. Sabry, Waleed Salmi, Tommi Mikael Selleslag, Dominik L. D. Shea, Thomas C. Silling, Gerda Sinisalo, Ulla Marjatta Sohn, Sang Kyun Staib, Peter and Szer, Jeff Theunissen, Koen Topcuoglu, Pervin Tyurina, Natalya G. Uvarov, Mikhail Wahid, Fadilah S. Abdul Yanez San Segundo, Lucrecia Yegin, Zeynep Arzu Yeh, Su-Peng Yip, Sze-Fai Yoon, Sung Soo Young, Jo-Anne H. Zachee, Pierre and Zaja, Francesco ZOE-HSCT Study Grp Collaborators

Abstract

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P

Published
2019

35. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation

Author

Gill, Harinder, primary, Yim, Rita, additional, Pang, Herbert H., additional, Lee, Paul, additional, Chan, Thomas S. Y., additional, Hwang, Yu‐Yan, additional, Leung, Garret M. K., additional, Ip, Ho‐Wan, additional, Leung, Rock Y. Y., additional, Yip, Sze‐Fai, additional, Kho, Bonnie, additional, Lee, Harold K. K., additional, Mak, Vivien, additional, Chan, Chi‐Chung, additional, Lau, June S. M., additional, Lau, Chi‐Kuen, additional, Lin, Shek‐Yin, additional, Wong, Raymond S. M., additional, Li, Wa, additional, Ma, Edmond S. K., additional, Li, Jun, additional, Panagiotou, Gianni, additional, Sim, Joycelyn P. Y., additional, Lie, Albert K. W., additional, and Kwong, Yok‐Lam, additional

Published
2020
Full Text
View/download PDF

36. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Author

Lin, Guo-Wang, primary, Xu, Caigang, additional, Chen, Kexin, additional, Huang, Hui-Qiang, additional, Chen, Jieping, additional, Song, Bao, additional, Chan, John K C, additional, Li, Wenyu, additional, Liu, Weiping, additional, Shih, Lee-Yung, additional, Chuang, Wen-Yu, additional, Kim, Won Seog, additional, Tan, Wen, additional, Peng, Rou-Jun, additional, Laurensia, Yurike, additional, Cheah, Daryl Ming Zhe, additional, Huang, DaChuan, additional, Cheng, Chee Leong, additional, Su, Yi-Jiun, additional, Tan, Soo-Yong, additional, Ng, Siok-Bian, additional, Tang, Tiffany Pooi Ling, additional, Han, Kyudong, additional, Wang, Vivien Ya-Fan, additional, Jia, Wei-Hua, additional, Pei, Zhong, additional, Li, Ya-Jun, additional, Gao, Song, additional, Shi, Yongyong, additional, Hu, Zhibin, additional, Zhang, Furen, additional, Zhang, Ben, additional, Zeng, Yi-Xin, additional, Shen, Hongbing, additional, He, Lin, additional, Ong, Choon Kiat, additional, Lim, Soon Thye, additional, Chanock, Stephen, additional, Kwong, Yok-Lam, additional, Lin, Dongxin, additional, Rothman, Nathaniel, additional, Khor, Chiea Chuen, additional, Lan, Qing, additional, Bei, Jin-Xin, additional, Au, Wing-Yan, additional, Chiu, Brian, additional, Fan, Lei, additional, Li, Zheng, additional, LAM, Tai Hing, additional, Liang, Raymond, additional, Yeh, Su-Peng, additional, Xu, Jun, additional, Ip, Dennis Kai Ming, additional, Li, Gandi, additional, Xu, Gang, additional, Wang, Xiaodong, additional, Bai, Ou, additional, Cai, Qing-Qing, additional, Xia, Yi, additional, Chen, Jie-Rong, additional, Luo, Chun-Ling, additional, Xiong, Xiang-Yu, additional, Zeng, Yanni, additional, Wei, Pan-Pan, additional, Liu, Chu-Jun, additional, Liu, Yu-Xiang, additional, Cao, Yu-Lu, additional, He, Shuai, additional, Liu, Yang, additional, Ha, Jeslin Chian Hung, additional, Khoo, Lay Poh, additional, Kee, Rebecca Xiangpin, additional, Tan, Jing, additional, Liu, Yanhui, additional, Zhang, Fen, additional, Feng, Yanfen, additional, Rao, Huilan, additional, Chng, Wee Joo, additional, Chan, Jason Yong Sheng, additional, Somasundaram, Nagavalli D/O, additional, Tao, Miriam, additional, Ras, Mohamad Farid Bin Harunal, additional, Yeoh, Kheng-Wei, additional, Goh, Yeow Tee, additional, Ong, Shin Yeu, additional, Grigoropoulos, Nicholas Francis, additional, Wong, Esther Kam Yin, additional, Pang, Jane Wan Lu, additional, Lim, Jing Quan, additional, Chia, Burton Kuan Hui, additional, Kim, Seok Jin, additional, Yoon, Sang Eun, additional, Choi, Seungkyu, additional, Kuo, Ching-Yuan, additional, Chen, Tsai-Yun, additional, Su, Yu-Chieh, additional, Huang, Wen-Tsung, additional, Lee, Ming-Yang, additional, Yao, Wenxiu, additional, Ngan, Kai-Cheong, additional, Liu, Herman, additional, Lee, Harold, additional, Yip, Sze-Fai, additional, Liu, Jie, additional, Li, Jianyong, additional, Rabkin, Charles S., additional, Berndt, Sonja, additional, Bassig, Bryan, additional, Hu, Wei, additional, Zhao, Mingfeng, additional, Li, Yuming, additional, Zhai, Qiongli, additional, Shao, Zonghong, additional, Qiu, Lugui, additional, Wang, Jianxiang, additional, Xu, Fu-Ping, additional, Chen, Ling, additional, Hou, Yu, additional, Xu, Shuangnian, additional, Huang, Zhen, additional, Xie, Mingling, additional, Li, Ming, additional, Zhong, Shilong, additional, Zhang, Yan, additional, Gu, Dongqing, additional, Wang, Xin, additional, Foo, Jia Nee, additional, Li, Zhiqiang, additional, Dai, Juncheng, additional, Sun, Liangdan, additional, Wang, Zhenzhen, additional, Liu, Hong, additional, Zhou, Hui, additional, Sun, Yonghu, additional, Koh, Woon-Puay, additional, Heng, Chew-Kiat, additional, Hong, Chew Soo, additional, Ahn, Jeeyun, additional, Park, Kyu Hyung, additional, Tin, Aung, additional, Gu, Jieruo, additional, Xia, Xiaojun, additional, Li, Bo, additional, and Yu, Xueqing, additional

Published
2020
Full Text
View/download PDF

37. A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

Author

Zhang, Chunxiao, primary, Leung, Garret MK, additional, Tsui, Sze Pui, additional, Ip, Ho-Wan, additional, Ma, Edmond S. K., additional, Au, Chun Hang, additional, Chan, Chris T.L., additional, Ng, Ka Lam Nelson, additional, Yip, Sze Fai, additional, Kho, Bonnie, additional, Lee, Harold K K, additional, LIU, Qing, additional, Leung, Thomas Wing Yan, additional, Kwong, Yok Lam, additional, and Leung, Anskar Yu Hung, additional

Published
2019
Full Text
View/download PDF

38. A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults

Author

Tsui, Sze Pui, primary, Alvin, Ip HW, additional, Zhang, Chunxiao, additional, Tang, Tommy W.F., additional, Lin, CH, additional, Cheung, Arthur, additional, Cheng, Grace, additional, So, Jason Chi Chiu, additional, Leung, S.Y., additional, Au, Tommy CH, additional, Ma, Edmond S. K., additional, Chan, Chris T.L., additional, Ng, Margaret, additional, Cheng, Kelvin CK, additional, Wong, Kit Fai, additional, Siu, Lisa L.P., additional, Yip, Sze Fai, additional, Lin, S.Y., additional, Lau, Szeman June, additional, Luk, T.H., additional, Lee, Harold K K, additional, Lau, Chi Kuen, additional, Kho, Bonnie, additional, Kwong, Yok Lam, additional, Javed, Asif, additional, and Leung, Anskar Yu Hung, additional

Published
2019
Full Text
View/download PDF

39. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms‐like tyrosine kinase 3

Author

Zhang, Chunxiao, primary, Lam, Stephen S. Y., additional, Leung, Garret M. K., additional, Tsui, Sze‐Pui, additional, Yang, Ning, additional, Ng, Nelson K. L., additional, Ip, Ho‐Wan, additional, Au, Chun‐Hang, additional, Chan, Tsun‐Leung, additional, Ma, Edmond S. K., additional, Yip, Sze‐Fai, additional, Lee, Harold K. K., additional, Lau, June S. M., additional, Luk, Tsan‐Hei, additional, Li, Wa, additional, Kwong, Yok‐Lam, additional, and Leung, Anskar Y. H., additional

Published
2019
Full Text
View/download PDF

40. Oral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study

Author

Gill, Harinder, primary, Kumana, Cyrus R., additional, Yim, Rita, additional, Hwang, Yu‐Yan, additional, Chan, Thomas S. Y., additional, Yip, Sze‐Fai, additional, Lee, Harold K. K., additional, Mak, Vivien, additional, Lau, June S. M., additional, Chan, Chi‐Chung, additional, Kho, Bonnie, additional, Wong, Raymond S. M., additional, Li, Wa, additional, Lin, Shek‐Yin, additional, Lau, Chi‐Kuen, additional, Ip, Ho‐Wan, additional, Leung, Rock Y. Y., additional, Lam, Clarence C. K., additional, and Kwong, Yok‐Lam, additional

Published
2019
Full Text
View/download PDF

42. Association of HLA‐B22 serotype with SARS‐CoV‐2 susceptibility in Hong Kong Chinese patients.

Author

Yung, Yuk‐Lin, Cheng, Chi‐Keung, Chan, Hoi‐Yun, Xia, Jenny T., Lau, Kin‐Mang, Wong, Raymond S. M., Wu, Alan K. L., Chu, Raymond W., Wong, Alice C. C., Chow, Eudora Y. D., Yip, Sze‐Fai, Leung, Jennifer N. S., Lee, Cheuk‐Kwong, and Ng, Margaret H. L.

Subjects
SARS-CoV-2, COVID-19, CHINESE people, VIRUS diseases, COMMUNICABLE diseases
Abstract

The coronavirus disease 2019 (COVID‐19) is a highly infectious disease caused by SARS‐CoV‐2. Since its first report in December 2019, COVID‐19 has evolved into a global pandemic causing massive healthcare and socioeconomic challenges. HLA system is critical in mediating anti‐viral immunity and recent studies have suggested preferential involvement of HLA‐B in COVID‐19 susceptibility. Here, by investigating the HLA‐B genotypes in 190 unrelated Chinese patients with confirmed COVID‐19, we identified a significant positive association between the B22 serotype and SARS‐CoV‐2 infection (p = 0.002, Bonferroni‐corrected p = 0.032). Notably, the B22 serotype has been consistently linked to susceptibility to other viral infections. These data not only shed new insights into SARS‐CoV‐2 pathogenesis and vaccine development but also guide better infection prevention/control. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Characterization of Genomic Landscape and Risk Stratification of De Novo Cytogenetically Normal Acute Myeloid Leukaemia

Author

Tsui, Sze Pui, primary, Tang, Tommy W.F., additional, Ip, Ho-Wan, additional, So, Jason Chi Chiu, additional, Au, Chun Hang, additional, Ma, Edmond S. K., additional, Chan, Chris TL, additional, Ng, Margaret, additional, Cheng, Kelvin C K, additional, Wong, Kit Fai, additional, Siu, Lisa L.P., additional, Yip, Sze Fai, additional, Lin, Sy, additional, Lau, Szeman June, additional, Luk, T.H., additional, Lee, Harold K K, additional, Lau, Chi Kuen, additional, Kho, Bonnie, additional, Zhang, Chunxiao, additional, Kwong, Yok Lam, additional, and Leung, Anskar Y.-H., additional

Published
2018
Full Text
View/download PDF

46. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.

Author

Gill, Harinder, Yim, Rita, Lee, Harold K. K., Mak, Vivien, Lin, Shek‐Ying, Kho, Bonnie, Yip, Sze‐Fai, Lau, June S. M., Li, Wah, Ip, Ho‐Wan, Hwang, Yu‐Yan, Chan, Thomas S. Y., Tse, Eric, Au, Wing‐Yan, Kumana, Cyrus R., Kwong, Yok‐Lam, Lin, Shek-Ying, Yip, Sze-Fai, Ip, Ho-Wan, and Hwang, Yu-Yan

Subjects
ACUTE promyelocytic leukemia, DISEASE remission, ARSENIC trioxide, DISEASE relapse, PROGRESSION-free survival
Abstract

Background: For patients who have acute promyelocytic leukemia (APL) in second complete remission (CR2), optimal postremission strategies remain undefined.Methods: The role of an oral arsenic trioxide (As2 O3 )-based regimen in the management of patients who had APL in CR2 was examined.Results: Seventy-three patients with APL in first relapse (R1) were studied. Oral As2 O3 -based reinduction resulted uniformly in CR2, irrespective of previous As2 O3 exposure. All patients received oral As2 O3 -based maintenance in CR2. At a median follow-up of 94 months (range, 9-205 months), 43 patients (58.9%) were still in CR2, and 49 (67.1%) had finished the planned 2-year CR2 maintenance with all-trans retinoic acid, oral As2 O3 , and ascorbic acid. Reinduction and maintenance treatments were well tolerated. Grade 1 and 2 headache occurred in 20 patients (27.4%). Hepatotoxicity, all in the form of transaminitis, occurred in 35 patients (47.9%; grade 1 and 2, n = 26; grade 3 and 4, n = 9). Three patients had self-limiting QTc prolongation. The 10-year leukemia-free survival rate was 56.8%. Thirty patients developed R2. Oral As2 O3 -based reinduction led to CR3 in 27 patients (90%). Post-CR3 strategies included autologous hematopoietic stem cell transplantation and oral As2 O3 maintenance. At a post-CR3 follow-up of 30 months (range, 3-166 months), 11 patients were still in CR3. The 5-year and 10-year overall survival rates in the R1 cohort were 79.5% and 67.3%, respectively. Prior receipt of oral As2 O3 maintenance in CR1 was the only risk factor for inferior leukemia-free survival. Central nervous system involvement occurred in 15 patients, including 5 who remained alive. Relapse during oral As2 O3 therapy was the only significant risk factor for central nervous system involvement.Conclusions: For patients with relapsed APL, As2 O3 remained effective despite repeated As2 O3 exposures. Oral As2 O3 maintenance was an effective postremission strategy for CR2. Cancer 2018;124:2316-26. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. Zopiclone Overdose Is an Important and Under‐Recognized Cause of Drug‐Induced Oxidative Hemolysis: A Case Series Identified by Heinz Body Test Request.

Author

Lam, Wing Kit, Law, Winnie Yim Fong, and Yip, Sze Fai

Subjects
*DRUG overdose, *GLUCOSE-6-phosphate dehydrogenase deficiency, *BIOCHEMISTRY, *CLINICAL toxicology, *BORDERLINE personality disorder
Abstract

The article discusses a case series that highlights zopiclone overdose as a significant and under-recognized cause of drug-induced oxidative hemolysis. The study, conducted in Hong Kong, identified zopiclone as the most frequent cause of oxidative hemolysis, particularly in females with depression or substance use disorders. The research emphasizes the importance of recognizing zopiclone as a potential cause of oxidative hemolysis and the challenges in diagnosing chronic zopiclone overdoses due to atypical presentations and delayed recognition. The study also raises concerns about the illegitimate dispensing of zopiclone and the need for increased awareness among clinicians. [Extracted from the article]

Published
2024
Full Text
View/download PDF

48. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.

Author

Zhang, Chunxiao, Lam, Stephen S. Y., Leung, Garret M. K., Tsui, Sze‐Pui, Yang, Ning, Ng, Nelson K. L., Ip, Ho‐Wan, Au, Chun‐Hang, Chan, Tsun‐Leung, Ma, Edmond S. K., Yip, Sze‐Fai, Lee, Harold K. K., Lau, June S. M., Luk, Tsan‐Hei, Li, Wa, Kwong, Yok‐Lam, Leung, Anskar Y. H., Tsui, Sze-Pui, Ip, Ho-Wan, and Au, Chun-Hang

Subjects
SORAFENIB, ACUTE myeloid leukemia, PROTEIN-tyrosine kinases, ACUTE myeloid leukemia treatment, DISEASE progression, RESEARCH, GENETIC mutation, HOMOGRAFTS, RESEARCH methodology, ANTINEOPLASTIC agents, CANCER relapse, PROGNOSIS, EVALUATION research, MEDICAL cooperation, DRUG administration, COMPARATIVE studies, TRANSFERASES, DRUG synergism, GENES, HEMATOPOIETIC stem cell transplantation, DRUG resistance in cancer cells, DISEASE remission
Abstract

Background: Omacetaxine mepesuccinate (OME) has antileukemic effects against acute myeloid leukemia (AML) carrying an internal tandem duplication of Fms-like tyrosine kinase 3 (FLT3-ITD). A phase 2 clinical trial was conducted to evaluate a combination treatment of sorafenib and omacetaxine mepesuccinate (SOME).Methods: Relapsed or refractory (R/R) or newly diagnosed patients were treated with sorafenib (200-400 mg twice daily) and OME (2 mg daily) for 7 (first course) or 5 days (second course onward) every 21 days until disease progression or allogeneic hematopoietic stem cell transplantation (HSCT). The primary endpoint was composite complete remission, which was defined as complete remission (CR) plus complete remission with incomplete hematologic recovery (CRi). Secondary endpoints were leukemia-free survival (LFS) and overall survival (OS).Results: Thirty-nine R/R patients and 5 newly diagnosed patients were recruited. Among the R/R patients, 28 achieved CR or CRi. Two patients showed partial remission, and 9 patients did not respond. Among the 5 newly diagnosed patients, 4 achieved CR, and 1 achieved CRi. The median LFS and OS were 5.6 and 10.9 months, respectively. Prior Fms-like tyrosine kinase 3 (FLT3) inhibitor exposure (P = .007), 2 or more inductions (P = .001), and coexisting IDH2 (P = .008) and RUNX1 mutations (P = .003) were associated with lower CR/CRi rates. HSCT consolidation and deep molecular responses (defined as an FLT3-ITD variant allelic frequency [VAF] ≤ 0.1% or a nucleophosmin 1 [NPM1] mutant VAF ≤ 0.01%) were associated with better OS and LFS. Prior FLT3 inhibitor exposure and 2 or more inductions were associated with inferior LFS.Conclusions: SOME was safe and effective for R/R and newly diagnosed FLT3-ITD AML. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results